Indivior pays $295M to DOJ, concludes legacy resolution agreement

Indivior Pharmaceuticals, Inc.

Paid $295M in full to DOJ using cash on hand, resolving 2020 Resolution Agreement.
Resolution Agreement terminated on November 20, 2025.
CEO Joe Ciaffoni says milestone removes significant liability and simplifies capital structure.
Company reaffirms commitment to compliance and transparency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.